Novel antibody with potential in Parkinson’s disease  

Neurons in a brain with Alzheimer's disease

Alchemab Therapeutics has been awarded a grant of $595,000 by The Michael J Fox Foundation for Parkinson’s Research (MJFF) to support its Parkinson’s disease (PD) programme. 

The grant will fund research performed at Alchemab following its identification of antibodies that target prostaglandin biology in PD, a potentially unique approach to treatment. Alchemab is researching the therapeutic effects of its resilient patient-derived antibody in PD.  

The grant was awarded through MJFF’s Parkinson’s Disease Therapeutics Pipeline Program. The programme seeks to advance testing of therapeutic developments that address unmet medical needs in people with PD. The programme is designed to fund therapeutic development with a clear focus to prevent, stop, or delay disease progression, or to reduce the challenges of daily symptoms. 

Alchemab’s antibodies were discovered using its platform which integrates advanced proteomics, bioinformatics, and machine learning in the analysis of patient samples to find signals associated with resilience to disease. Using samples from patients predisposed to PD symptoms and samples from patients with a typical disease course, Alchemab identified a target it believes may contribute to disease resistance. Its research explores how the prostaglandin pathway impacts disease progression, using comprehensive genetic and molecular analyses.   

In addition, it is applying its computation resources to mine large PD datasets like the Parkinson’s Progression Markers Initiative (PPMI) to identify novel targets.   

Young Kwon, Chief Executive Officer of Alchemab, said: “This exciting programme is another example of the power of a patient-led, unbiased approach to target and therapeutics discovery. Alongside our programmes, which have the potential to impact frontotemporal dementia, Huntington’s and Alzheimer’s disease, we hope that our novel PD programme will be transformative for patients and unlock new disease understanding.”  

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free